Jacobs Levy Equity Management’s Astria Therapeutics ATXS Stock Holding History

Jacobs Levy Equity Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-152,732	Closed	-$1.17M	–	941
2023 Q4	$1.17M	Sell	152,732 -8,905	-6%	-$49.2K	0.01%	688
2023 Q3	$1.21M	Buy	161,637 +31,856	+25%	+$272K	0.01%	643
2023 Q2	$1.08M	Buy	129,781 +119,108	+1,116%	+$1.37M	0.01%	684
2023 Q1	$142K	Buy	+10,673	New	+$144K	﹤0.01%	922
2020 Q4	–	Sell	-8,695	Closed	-$323K	–	1016
2020 Q3	$323K	Buy	+8,695	New	+$345K	﹤0.01%	878
2019 Q1	–	Sell	-5,624	Closed	-$147K	–	954
2018 Q4	$147K	Buy	+5,624	New	+$213K	﹤0.01%	922
2018 Q3	–	Sell	-1,655	Closed	-$95K	–	983
2018 Q2	$95K	Sell	1,655 -694	-30%	-$64K	﹤0.01%	994
2018 Q1	$255K	Buy	+2,349	New	+$235K	﹤0.01%	888

Other funds holding ATXS

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management's ATXS Position: Q1 2024 in Review

Jacobs Levy Equity Management sold out of Astria Therapeutics (ATXS) in Q1 2024, closing a stake of 152,732 shares — an estimated $1.17M sold.

Jacobs Levy Equity Management first reported a position in ATXS in Q1 2018 and held it in 8 quarters. The position peaked at $1.21M in Q3 2023. 102 funds tracked by Wall St. Rank hold ATXS as of Q1 2024.

Jacobs Levy Equity Management reported no remaining Astria Therapeutics position as of Q1 2024 after selling out during the quarter.
Jacobs Levy Equity Management sold 152,732 Astria Therapeutics shares in Q1 2024, an estimated $1.17M.
Jacobs Levy Equity Management first reported a position in Astria Therapeutics in Q1 2018 and held it in 8 quarters.
Jacobs Levy Equity Management's Astria Therapeutics position peaked at $1.21M in Q3 2023.
102 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2024, filed 15 May 2024.